The switch gets stuck in the on position. Cells multiply without restraint.
For generations, pancreatic cancer has occupied a grim corner of medicine where science could observe but rarely intervene — a disease driven by a genetic mutation long considered beyond reach. In the spring of 2026, a drug called daraxonrasib emerged from clinical trials with results that quietly rewrote that assumption: by finding an indirect path to the previously untouchable KRAS protein, it nearly doubled how long patients with advanced disease could expect to live. It is not a cure, but in a field where progress has been measured in weeks, it represents a fundamental shift in what is now believed possible.
- Pancreatic cancer has long been one of medicine's most stubborn failures — nearly 97% of metastatic patients dead within five years, with chemotherapy offering delay but never real hope.
- The KRAS mutation driving over 90% of these tumors was considered undruggable for decades, its protein surface too smooth for conventional medicines to grip.
- Daraxonrasib sidesteps that barrier entirely, using a cellular helper molecule called cyclophilin A as a bridge to block KRAS indirectly — a workaround that trial results suggest is genuinely effective.
- In 500 patients, median survival jumped from 6.7 to 13.2 months, with a 60% reduction in death risk — numbers that stunned a field accustomed to incremental gains.
- Side effects are significant, with severe skin rashes affecting most patients, yet those on the drug reported better quality of life and fewer treatment discontinuations than those on chemotherapy.
- FDA approval is expected within months, and for patients who have had almost nothing to reach for, that timeline carries the weight of something long overdue.
Pancreatic cancer has long been defined by what medicine cannot do. The disease hides until it has already spread, produces few early symptoms, and resists treatment with unusual efficiency. At its genetic core sits a mutation in the KRAS gene — a stuck switch commanding cells to multiply without limit. For decades, the protein this gene produces was considered impossible to target directly, its surface offering no foothold for drugs. Oncologists were left with chemotherapy: effective at destruction, indiscriminate in what it destroyed.
That changed on May 31, 2026, when Revolution Medicines announced phase 3 trial results for daraxonrasib, an oral drug tested in 500 patients with metastatic pancreatic cancer who had already undergone prior treatment. The drug nearly doubled median survival — 13.2 months compared to 6.7 months on standard chemotherapy — and cut the risk of death by 60 percent. The mechanism is precise where chemotherapy is blunt: daraxonrasib binds to a naturally occurring cellular molecule called cyclophilin A, which then latches onto the mutated KRAS protein and silences the signals driving tumor growth.
The trade-offs are real. Severe skin rashes affected more than 86 percent of patients, and mouth ulcers, nausea, and diarrhea were common. Yet patients on daraxonrasib were less likely to abandon treatment than those on chemotherapy, and they reported meaningfully better quality of life. The toxicity came with something chemotherapy could not provide: more time.
Revolution Medicines is now pursuing FDA approval and international regulatory review. Given the severity of the disease and the scale of the survival benefit, expedited review is likely. For a cancer that has resisted every attempt at precision medicine, daraxonrasib does not represent a cure — but it represents the first real proof that the genetic machinery behind pancreatic cancer can be interrupted, and that proof alone changes the horizon for patients who previously had almost none.
For decades, pancreatic cancer has been a death sentence. Among patients diagnosed with metastatic pancreatic cancer between 2015 and 2021, roughly 97 percent were dead within five years. The disease kills so efficiently because it hides. There are no reliable screening tests. In its early stages, it produces almost no symptoms. By the time a patient notices yellowing skin or abdominal pain, the cancer has usually already spread to other organs. By then, the standard treatment—chemotherapy—can only slow what it cannot stop.
The reason pancreatic cancer resists treatment lies in its genetics. More than 90 percent of pancreatic tumors are driven by mutations in a gene called KRAS. This gene produces proteins that act like switches, turning cell growth on and off. When KRAS mutates, the switch gets stuck in the on position. Cells multiply without restraint. For decades, scientists considered KRAS untouchable. The protein's surface is too smooth, lacking the molecular pockets where traditional drugs could attach and flip the switch back off. Without a way to target KRAS directly, oncologists were left with chemotherapy—a blunt instrument that destroys cancer cells by destroying everything around them, poisoning healthy tissue in the process.
That calculus has shifted. On May 31, 2026, Revolution Medicines announced results from a phase 3 clinical trial of a new drug called daraxonrasib. The trial involved 500 patients with metastatic pancreatic cancer who had already received prior treatment. The results were striking: daraxonrasib nearly doubled median survival. Patients on the new drug survived an average of 13.2 months from diagnosis, compared to 6.7 months for those on standard chemotherapy. The drug reduced the risk of death by 60 percent.
Daraxonrasib works through an elegant workaround. Instead of attacking KRAS directly, the drug binds to a molecule called cyclophilin A, which exists naturally inside cells and helps proteins fold into their final three-dimensional shape. This complex then latches onto the mutated KRAS protein and blocks the signals that tell cancer cells to multiply. It is precision medicine—a targeted strike rather than scorched earth.
The side effects are real. More than 86 percent of patients in the trial developed severe skin rashes. Many experienced stomatitis, the painful swelling and ulceration of mouth tissue. Diarrhea, nausea, and vomiting were common. Yet patients on daraxonrasib were far less likely to stop treatment because of serious adverse effects compared to those on chemotherapy. They reported better quality of life and less pain. The toxicity, while present, came with a trade-off that chemotherapy could not offer: more time.
The drug is now moving toward regulatory review. Revolution Medicines plans to seek formal approval from the FDA and regulatory agencies worldwide. Given that advanced pancreatic cancer is notoriously difficult to treat, therapies showing meaningful survival gains often receive expedited or priority review. If approved, daraxonrasib could reach patients within months. For a disease that has long been considered untreatable, that timeline represents something close to a miracle—not a cure, but a genuine reprieve, and the first proof that the genetic engine driving pancreatic cancer can, in fact, be stopped.
Citações Notáveis
For decades, scientists considered KRAS impossible to target with drugs because the protein's surface is too smooth and lacks the molecular pockets where traditional medications could attach.— Oncologist and clinical trial researcher (paraphrased from source)
A Conversa do Hearth Outra perspectiva sobre a história
Why did it take so long to find a drug that works against KRAS?
Because the protein itself is almost impossible to grab onto. Imagine trying to pick up a marble with tweezers—the surface is too smooth. For decades, that seemed like a permanent dead end.
So daraxonrasib doesn't actually grab KRAS directly?
No. It grabs something else—a helper molecule called cyclophilin A—and that complex then holds onto KRAS and shuts it down. It's indirect, but it works.
The survival numbers are striking. But 13 months is still not very long.
It's not. But it's double what patients had before. And it comes with fewer side effects than chemotherapy. For someone facing pancreatic cancer, that's the difference between a few months of suffering and a few more months of actual life.
What about those skin rashes? 86 percent is almost everyone.
They're severe, but manageable. The real point is that patients on daraxonrasib were less likely to quit treatment because of side effects. With chemotherapy, the toxicity is so brutal that many people stop. Here, people stay on the drug.
What happens next?
The FDA reviews the data. If they approve it—and they likely will, given the results—patients could start using it within months. That's the immediate horizon.
Does this cure pancreatic cancer?
No. But it transforms it from a disease with almost no options into one where targeted therapy actually works. That's not a cure. It's a beginning.